Biopower Operations Corp

2023 Q3 Form 10-Q Financial Statement

#000149315223029788 Filed on August 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $0.00 $522.4K
YoY Change -100.0%
Cash & Equivalents $522.4K
Short-Term Investments
Other Short-Term Assets $77.59K
YoY Change
Inventory $12.89K $12.89K
Prepaid Expenses $77.59K
Receivables $331.00 $331.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $13.22K $613.2K
YoY Change -97.84%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $4.00 $3.00
YoY Change 33.33%
TOTAL ASSETS
Total Short-Term Assets $13.22K $613.2K
Total Long-Term Assets $4.00 $3.00
Total Assets $13.22K $613.2K
YoY Change -97.84%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.576M $2.374M
YoY Change 50.65% 17.23%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $2.625M $3.413M
YoY Change -23.09% 41.45%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.889M $5.786M
YoY Change 19.06% 30.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.889M $5.786M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $6.889M $5.786M
YoY Change 19.06% 30.4%
SHAREHOLDERS EQUITY
Retained Earnings -$15.74M -$9.569M
YoY Change 64.45%
Common Stock $4.588K $4.564K
YoY Change 0.53%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.876M -$5.173M
YoY Change
Total Liabilities & Shareholders Equity $13.22K $613.2K
YoY Change -97.84%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001510832
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
usd
CY2022Q4 us-gaap Bank Overdrafts
BankOverdrafts
usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
usd
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
usd
us-gaap Share Based Compensation
ShareBasedCompensation
usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Stock Issued1
StockIssued1
usd
BOPO Derivative Resolution
DerivativeResolution
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-05-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53274
dei Entity Registrant Name
EntityRegistrantName
BioPower Operations Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4460232
dei Entity Address Address Line1
EntityAddressAddressLine1
20801 Biscayne Blvd
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 403
dei Entity Address City Or Town
EntityAddressCityOrTown
Aventura
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33180
dei City Area Code
CityAreaCode
(786)
dei Local Phone Number
LocalPhoneNumber
923-0272
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47538859 shares
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
825 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
331 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
331 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
12893 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
12893 usd
CY2023Q2 us-gaap Assets
Assets
13224 usd
CY2022Q4 us-gaap Assets
Assets
14049 usd
CY2023Q2 us-gaap Bank Overdrafts
BankOverdrafts
245 usd
CY2023Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
375000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
375000 usd
CY2023Q2 BOPO Convertible Debt Variable Priced Conversion Current
ConvertibleDebtVariablePricedConversionCurrent
211750 usd
CY2022Q4 BOPO Convertible Debt Variable Priced Conversion Current
ConvertibleDebtVariablePricedConversionCurrent
157167 usd
CY2023Q2 us-gaap Other Notes Payable
OtherNotesPayable
193667 usd
CY2022Q4 us-gaap Other Notes Payable
OtherNotesPayable
193667 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
313464 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
262050 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6889184 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5953792 usd
CY2023Q2 BOPO Common Stock Owed Value
CommonStockOwedValue
125000 usd
CY2022Q4 BOPO Common Stock Owed Value
CommonStockOwedValue
125000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45867915 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45867915 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45625000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45625000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
4588 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4564 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
8730014 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4279317 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15736462 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-10349524 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6875960 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5939743 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13224 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14049 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
246700 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
446700 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
248773 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
681139 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4446448 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
212443 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4497298 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
363868 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
4695221 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
212443 usd
us-gaap Operating Expenses
OperatingExpenses
5178437 usd
us-gaap Operating Expenses
OperatingExpenses
363868 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4695221 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
34257 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5178437 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
82832 usd
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-16900 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-66590 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-62110 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-47395 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-208501 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-94790 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4757331 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13138 usd
us-gaap Net Income Loss
NetIncomeLoss
-5386938 usd
us-gaap Net Income Loss
NetIncomeLoss
-11958 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.10
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.10
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45867915 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45867915 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45597826 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45597826 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45762474 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45762474 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45302198 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45302198 shares
us-gaap Net Income Loss
NetIncomeLoss
-5386938 usd
us-gaap Net Income Loss
NetIncomeLoss
-11958 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4423545 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
66583 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-66590 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
331 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
77593 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12983 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
823575 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-191071 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
5575 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
470238 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1070 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
176302 usd
us-gaap Proceeds From Bank Debt
ProceedsFromBankDebt
245 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
249991 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
245 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
249991 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-825 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
426293 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
825 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
95973 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
522266 usd
us-gaap Stock Issued1
StockIssued1
12000 usd
BOPO Derivative Resolution
DerivativeResolution
15176 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-5409998 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
249991 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13138 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5173145 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6542174 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4423545 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4757331 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6875960 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-5411178 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
249991 usd
us-gaap Net Income Loss
NetIncomeLoss
-11958 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-5173145 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5939743 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5939743 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
12000 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
15176 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4423545 usd
us-gaap Net Income Loss
NetIncomeLoss
-5386938 usd
us-gaap Net Income Loss
NetIncomeLoss
-5386938 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6875960 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6875960 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-15736462 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-6875960 usd
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45867915 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45625000 shares
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_847_eus-gaap--UseOfEstimates_zBQPh8yZxuKi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_869_ze3o4CzsBXGh">Use of Estimates</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to income taxes and contingencies. The Company bases its estimates on historical experience, known or expected trends and various other assumptions that are believed to be reasonable given the quality of information available as of the date of these financial statements. The results of these assumptions provide the basis for making estimates about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Actual results could differ from these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Inventory Net
InventoryNet
12893 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
12893 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_z1Ij1WPAG0W6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span><span id="xdx_86C_ziiriS69ETd6">Concentration</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Two customers, including one related party, account for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220301__20220531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zWIyJBmmOHlb" title="Concentration risk, percentage">100</span>% of sales during the three months ended May 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Five customers, including two related parties, account for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20211201__20220531__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--FiveCustomersMember_zOi348YuftH" title="Concentration risk, percentage">100</span>% of sales during the six months ended May 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Bank Overdrafts
BankOverdrafts
245 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
825 usd
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45625000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45867915 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
900000 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
900000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Notes Payable
NotesPayable
694198 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
694198 usd
CY2015Q3 us-gaap Notes Payable
NotesPayable
113031 usd
CY2015Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.08 pure
CY2023Q2 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
365107 usd
CY2022Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
275071 usd
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000 shares
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
1.00
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45625000 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45625000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45000000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
900000 shares
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
900000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4423545 usd
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7709607 usd
CY2022Q4 BOPO Cash Placement Fee Rate
CashPlacementFeeRate
0.04 pure
CY2023Q2 us-gaap Officers Compensation
OfficersCompensation
180000 usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
112346 shares

Files In Submission

Name View Source Status
0001493152-23-029788-index-headers.html Edgar Link pending
0001493152-23-029788-index.html Edgar Link pending
0001493152-23-029788.txt Edgar Link pending
0001493152-23-029788-xbrl.zip Edgar Link pending
bopo-20230531.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
bopo-20230531_cal.xml Edgar Link unprocessable
bopo-20230531_def.xml Edgar Link unprocessable
bopo-20230531_lab.xml Edgar Link unprocessable
bopo-20230531_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending